Stockreport

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting [Yahoo! Finance]

Alterity Therapeutics Limited - American Depositary Shares  (ATHE) 
PDF ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses MELBOURNE, Australia and SAN FRA [Read more]